Needham Remains Cautious On Vivus Ahead Of 4Q14 Results


In a research report published Thursday, Needham analyst Alan Carr reiterated a Hold rating on VIVUS, Inc. (NASDAQ:VVUS), as the company is expected to announce fourth-quarter financial results in Feb 2015. No price target was provided.

Carr noted, “Based on IMS/Symphony prescription data, we are revising our Qsymia sales estimates down to $13M (was $14.4M). Market penetration remains a challenge. We believe this is due to consumer awareness. Peak sales potential may be modest ($250-500M), given resource constraints.”

The analyst added, “Qsymia held a consistent 6.4-6.7% TRX market share throughout 2014 according to monthly IMS prescription service data. Overall prescriptions for weight loss drugs, however, were down in 4Q14. This is consistent with a seasonal decline seen in 2013.”

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Alan Carr has a total average return of 40.2% and a 71.8% success rate. Carr has a -11.0% average return when recommending VVUS, and is ranked #6 out of 3510 analysts.